Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Séverine Pitel"'
Autor:
Edmund A. M. Neugebauer, Ana Rath, Sunya-Lee Antoine, Michaela Eikermann, Doerthe Seidel, Carsten Koenen, Esther Jacobs, Dawid Pieper, Martine Laville, Séverine Pitel, Cecilia Martinho, Snezana Djurisic, Jacques Demotes-Mainard, Christine Kubiak, Vittorio Bertele, Janus C. Jakobsen, Silvio Garattini, Christian Gluud
Publikováno v:
Trials, Vol 18, Iss 1, Pp 1-10 (2017)
Abstract Background Medical devices play an important role in the diagnosis, prevention, treatment and care of diseases. However, compared to pharmaceuticals, there is no rigorous formal regulation for demonstration of benefits and exclusion of harms
Externí odkaz:
https://doaj.org/article/789d713ad1c644c6b9323d8a1747ace3
Autor:
Michaela Eikermann, Janus Christian Jakobsen, Vittorio Bertele, Séverine Pitel, Dawid Pieper, Christian Gluud, Snezana Djurisic, Jacques Demotes-Mainard, Esther Jacobs, Cecilia Martinho, Christine Kubiak, Carsten Koenen, Silvio Garattini, Martine Laville, Doerthe Seidel, Edmund Neugebauer, Sunya Lee Antoine, Ana Rath
Publikováno v:
Trials, Vol 18, Iss 1, Pp 1-10 (2017)
Trials
Trials, BioMed Central, 2016, 18 (1), pp.427. ⟨10.1186/s13063-017-2168-0⟩
Trials, 2016, 18 (1), pp.427. ⟨10.1186/s13063-017-2168-0⟩
Trials
Trials, BioMed Central, 2016, 18 (1), pp.427. ⟨10.1186/s13063-017-2168-0⟩
Trials, 2016, 18 (1), pp.427. ⟨10.1186/s13063-017-2168-0⟩
Background Medical devices play an important role in the diagnosis, prevention, treatment and care of diseases. However, compared to pharmaceuticals, there is no rigorous formal regulation for demonstration of benefits and exclusion of harms to patie
Autor:
Séverine Pitel, Emmanuel Teiger, Christelle Ratignier, Karine Szwarcenstein, Bernard Avouac, Odile Sechoy, Patricia Descamps-Mandine, Lucie Aubourg, Marcel Goldberg, Claire Coqueblin, François Parquin, Bernard Guillot, Serge Hanoka, Cédric Carbonneil, André Tanti, Karine Levesque, Nicolas Thevenet, Michel Cucherat, Anne Josseran
Publikováno v:
Therapies. 69:303-312
Resume Le dispositif medical se caracterise notamment par une grande heterogeneite (de l’abaisse langue a la prothese de hanche, en passant par le dispositif non implantable a invasif), un cycle de vie court des produits avec des innovations increm
Autor:
Alain Francillon, Gisèle Pickering, Chantal Belorgey, Michel Abiteboul, Bernard Bégaud, Jehan-Michel Behier, Bénédicte Chauvin, Antoine Cournot, Rémy Defrance, Jean-Paul Demarez, Élisabeth Devilliers, Vincent Diebolt, Bertrand Diquet, Yves Donazzolo, Muriel Echemann, Christian Funck-Brentano, Patrick Genissel, Nadine Houedé, Jean-Marc Husson, Philippe Lefevre, Isabelle Macquin-Mavier, Brigitte Marchenay, Christine Marey, Laurence Negres-Pages, Séverine Pitel, Valérie Plattner, Christine Roy, Michel Sibille, Nicolas Simon, Claire Thalamas, Dominique Tremblay, Tony Waegemans
Publikováno v:
Therapies. 64:155-159
The working group focused on defining exploratory trials on medicinal products and developing recommendations for their implementation in France (notably concerning non-clinical requirements, the pharmaceutical quality of the investigational medical
Autor:
Karine, Levesque, Claire, Coqueblin, Bernard, Guillot, Lucie, Aubourg, Bernard, Avouac, Cédric, Carbonneil, Michel, Cucherat, Patricia, Descamps-Mandine, Serge, Hanoka, Marcel, Goldberg, Anne, Josseran, François, Parquin, Séverine, Pitel, Christelle, Ratignier, Odile, Sechoy, Karine, Szwarcenstein, André, Tanti, Emmanuel, Teiger, Nicolas, Thevenet
Publikováno v:
Therapie. 69(4)
Autor:
Lucie Aubourg, Karine Levesque, Emmanuel Teiger, Serge Hanoka, Marcel Goldberg, Patricia Descamps-Mandine, Nicolas Thevenet, Anne Josseran, Christelle Ratignier, Séverine Pitel, François Parquin, Karine Szwarcenstein, Bernard Avouac, Odile Sechoy, André Tanti, Michel Cucherat, Claire Coqueblin, Cédric Carbonneil, Bernard Guillot
Publikováno v:
Therapie. 69(4)
Medical devices are characterized notably by a wide heterogeneity (from tongue depressors to hip prostheses, and from non-implantable to invasive devices), a short life cycle with recurrent incremental innovations (from 18 months to 5 years), and an